Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2004545 | 1.00 | TLR4 (0.86) | TLR4LY96 | |
| SCHEMBL12621288 | 0.93 | TLR4 (1.00) | TLR4LY96 | |
| SCHEMBL12621433 | 0.93 | TLR4 (1.00) | TLR4LY96 | |
| SCHEMBL2004544 | 0.93 | TLR4 (1.00) | TLR4LY96 | |
| SCHEMBL13705667 | 0.93 | TLR4 (1.00) | TLR4LY96 | |
| SCHEMBL6062580 | 0.93 | TLR4 (1.00) | TLR4LY96 | |
| SCHEMBL12568788 | 0.93 | TLR4 (1.00) | TLR4LY96 | |
| SCHEMBL14376659 | 0.93 | TLR4 (1.00) | TLR4LY96 | |
| SCHEMBL12568787 | 0.93 | TLR4 (1.00) | TLR4LY96 | |
| SCHEMBL93754 | 0.93 | TLR4 (1.00) | TLR4LY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199460-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION (US) | 2003-10-23 | — | — | US | claimed |
| US-20030092643-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION | 2003-05-15 | — | — | US | claimed |
| US-12551552-B2 | Antigenic glycoprotein E polypeptides, compositions, and methods of use thereof | MERCK SHARP & DOHME LLC (US) | 2026-02-17 | — | — | US | disclosed |
| US-20250161420-A1 | PEPTIDE CONJUGATE VACCINE COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC (US) | 2025-05-22 | — | — | US | disclosed |
| US-12295998-B2 | Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates | MERCK SHARP & DOHME LLC (US) | 2025-05-13 | — | — | US | disclosed |
| US-12280107-B2 | Pneumococcal conjugate vaccine formulations | MERCK SHARP & DOHME LLC (US) | 2025-04-22 | — | — | US | disclosed |
| US-12226470-B2 | Pneumococcal dosing regimen | WYETH LLC (US) | 2025-02-18 | — | — | US | disclosed |
| US-12161721-B2 | Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein | MERCK SHARP & DOHME LLC (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240398925-A1 | COMPOSITIONS COMPRISING STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE-PROTEIN CONJUGATES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240342263-A1 | METHODS FOR MAKING POLYSACCHARIDE-PROTEIN CONJUGATES | MERCK SHARP & DOHME LLC (US) | 2024-10-17 | — | — | US | disclosed |
| US-20240327502-A1 | ANTIBODIES THAT BIND METAPNEUMOVIRUS, ANTIGENIC METAPNEUMOVIRUS PROTEINS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-10-03 | — | — | US | disclosed |
| US-20060171955-A1 | Process for increasing rsv surface glycoprotein yields using a mutant strain of rsv | WYETH HOLDINGS CORPORATION | 2006-08-03 | — | — | US | disclosed |
| WO-2006012425-A2 | PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR | CORIXA CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006004874-A1 | RECOMBINANT RSV STRAINS WITH ALTERED G PROTEIN | WYETH HOLDINGS CORPORATION (US) | 2006-01-12 | — | — | WO | disclosed |
| EP-1603940-A2 | PROCESS FOR INCREASING RSV SURFACE GLYCOPROTEIN YIELDS USING A MUTANT STRAIN OF RSV | Wyeth Holdings Corporation (US) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005116064-A2 | ALTERED FIBRONECTIN-BINDING PROTEIN OF STAPHYLOCOCCUS AUREUS | WYETH (US) | 2005-12-08 | — | — | WO | disclosed |
| EP-1601381-A2 | POLYSACCHARIDE - STAPHYLOCOCCAL SURFACE ADHESIN CARRIER PROTEIN CONJUGATES FOR IMMUNIZATION AGAINST NOSOCOMIAL INFECTIONS | Wyeth Holdings Corporation (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20050107600-A1 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor | CORIXA CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | US | disclosed |
| WO-2004083397-A2 | PROCESS FOR INCREASING RSV SURFACE GLYCOPROTEIN YIELDS USING A MUTANT STRAIN OF RSV | WYETH HOLDINGS CORPORATION (US) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004080490-A2 | POLYSACCHARIDE - STAPHYLOCOCCAL SURFACE ADHESIN CARRIER PROTEIN CONJUGATES FOR IMMUNIZATION AGAINST NOSOCOMIAL INFECTIONS | WYETH HOLDINGS CORPORATION (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199460-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | DNPEP, CD68, MGAT3 | TLR4 70/4885LY96 87/4885 |
| US-20030092643-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | DNPEP, CD68, MGAT3 | TLR4 70/4885LY96 87/4885 |
| US-20050107600-A1 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor | DDOST, AGL, GALE | TLR4 661/4885LY96 372/4885 |
| US-12551552-B2 | Antigenic glycoprotein E polypeptides, compositions, and methods of use thereof | MICA, FCGR3B, CD74 | TLR4 2235/4885LY96 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.